About Limula
Limula is a company based in La Tour De Peilz (Switzerland) founded in 2020 by Luc Henry and Yann Pierson. Limula has raised $6.8 million across 4 funding rounds from investors including University of Oxford, Open-i and Life Extension Ventures. Limula offers products and services including Unified Manufacturing Platform and Cell Processing Unit. Limula operates in a competitive market with competitors including PBS Biotech, m2p-labs, Membio, Bionet Engineering and MicroBiopharm Japan, among others.
- Headquarter La Tour De Peilz, Switzerland
- Founders Luc Henry, Yann Pierson
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Limula Sa
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$6.8 M (USD)
in 4 rounds
-
Latest Funding Round
$6.8 M (USD), Seed
May 21, 2024
-
Investors
University of Oxford
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Limula
Limula offers a comprehensive portfolio of products and services, including Unified Manufacturing Platform and Cell Processing Unit.
Automated device combining bioreactor and centrifuge for therapy production
Modular system for scalable cell therapy development and processing
People of Limula
Unlock access to complete
Funding Insights of Limula
Limula has successfully raised a total of $6.8M across 4 strategic funding rounds. The most recent funding activity was a Seed round of $6.8 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Limula
Limula has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include University of Oxford, Open-i and Life Extension Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on tech sectors
|
Locked | Locked | Locked | |
|
Venture capital firm focused on science and tech-driven startups
|
Locked | Locked | Locked | |
|
Zühlke is recognized as a global transformation partner focused on engineering and innovation.
|
Locked | Locked | Locked |
Investor details for Limula
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Limula
Investment portfolio details for Limula
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Limula
Detailed financials for Limula
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Limula Comparisons
Peer comparison for Limula
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Limula
Limula operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PBS Biotech, m2p-labs, Membio, Bionet Engineering and MicroBiopharm Japan, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of single-use bioreactors for the production of vaccines, therapeutic proteins, and cell therapies
|
|
| Locked | Locked | Locked |
Micro-bioreactors are provided for screening and bioprocess development.
|
|
| Locked | Locked | Locked |
Developer of single-use bioreactors for cell and gene therapies
|
|
| Locked | Locked | Locked |
Manufactures bioreactors, TFF systems, and software for biopharma and agri-food applications.
|
|
| Locked | Locked | Locked |
Contract research and discovery services are provided to biopharma firms.
|
Detailed competitors of Limula
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Limula
Complete news archive for Limula
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Limula
Limula was founded in 2020 and raised its 1st funding round 2 years after it was founded.
Limula is headquartered in La Tour De Peilz, Switzerland. It is registered at La Tour De Peilz, Vaud, Switzerland.
Luc Henry is the current CEO of Limula. They have also founded this company.
Limula is a funded company, having raised a total of $6.8M across 4 funding rounds to date.
Limula was founded in 2020 as a provider of modular solutions for on-demand and scaled manufacturing of cell therapies. Operations focus on a proprietary bioreactor platform that integrates multiple manufacturing steps into a single automated device, supported by end-to-end process analytics. The company operates in the biotechnology sector, with services centered on cell therapy production efficiency. Based in Switzerland, as indicated by its domain.
Limula's top competitors include PBS Biotech, m2p-labs and Membio.
Limula offers Unified Manufacturing Platform and Cell Processing Unit.
Limula has 9 investors. Key investors include University of Oxford, Open-i, Life Extension Ventures, Verve Ventures, and Zühlke.